EICHOR
● Active Not Recruiting
Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients
Condition: Osteosarcoma · Sponsor: UNICANCER
About this study
Trial evaluating the impact on efficacy of mifamurtide as add-on treatment to post-operative chemotherapy compared to post-operative chemotherapy alone in first-line treatment of patients with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (31)
| CHU Amiens-Picardie - Service d'oncologie hématologie pédiatrique | Amiens, France | — |
| CHU d'Angers - Service d'oncologie pédiatrique | Angers, France | — |
| Institut Bergonié - Service d'oncologie médicale | Bordeaux, France | — |
| CHU de Caen - Service d'oncologie hématologie pédiatrique | Caen, France | — |
| CHU de Grenoble - Service d'oncologie hématologie pédiatrique | La Tronche, France | — |
| Centre Oscar Lambret - Unité d'onco-pédiatrie | Lille, France | — |
| Centre Léon Bérard - IHOPE | Lyon, France | — |
| Centre Léon Bérard - Service d'oncologie médicale | Lyon, France | — |
| Hôpital de la Timone - service d'oncologie médicale | Marseille, France | — |
| Hôpital de la Timone - Service d'oncologie pédiatrique | Marseille, France | — |
| CHU Arnaud de Villeneuve - Onco-hématologie pédiatrique | Montpellier, France | — |
| Institut régional du Cancer de Montpellier - Service d'oncologie médicale | Montpellier, France | — |
+ 19 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03643133